At the Saitama Prefectural Children’s Medical Center, one teenage male patient has died, and two others are in critical condition after receiving intrathecal chemotherapy for leukemia. The hospital held a press conference on the 11th to announce that cerebrospinal fluid from all three patients had shown the presence of vinca alkaloid, a drug that should not have been used in that context. This alarming discovery prompted the hospital to report the incident to the Saitama Prefectural Police on the 10th, suggesting potential criminal implications.

The affected patients all showed neurological symptoms after the intrathecal administration of the chemotherapy drugs. The teenager experienced severe pain in his thigh following the injection on October 22 last year and subsequently passed away on February 6 this year. The other two, aged under ten and in their teens, reported similar issues and are currently on ventilators. The hospital director indicated that the patients were supposed to be treated exclusively with approved anticancer drugs, revealing a grave lapse in the expected treatment protocols, leading to a serious investigation.

The incident has raised significant concerns regarding patient safety and medication administration practices within the medical facility. Authorities are likely to undertake a thorough examination of hospital protocols to ensure such catastrophic errors do not recur. The implications of this situation extend beyond individual patient care, potentially impacting wider trust in pediatric hospital practices in Japan and prompting calls for stricter regulatory measures for the administration of chemotherapy drugs.